(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCPK (Pink Sheets) where the stock traded under the symbol “AIMD”.)

(Note: Ainos, Inc. priced its NASDAQ uplisting/unit offering on Aug. 8, 2022, by selling 780,000 units – sharply exceeding the 462,963 units in the prospectus – and pricing them at $4.25 per unit – far below the assumed offering price of $8.77 on a price range of $7.00 to $9.00. The public offering raised $3.315 million. The number of units and the offering price per unit were adjusted to reflect a 1-for-15 reverse stock split that became effective at 8 p.m. on Monday, Aug. 8, 2022, the company said in a news release. This is a greater ratio than the 1-for-12 reverse stock split cited in the prospectus. Each unit consists of one share of common stock and one warrant to buy one share of common stock. The company’s stock and warrants started trading on Tuesday, Aug. 9, 2022, on the NASDAQ under the symbol “AIMD” for the stock and “AIMDW” for the warrants.)

Ainos, Inc. is a diversified medical technology (med tech) company focused on the development of novel point-of-care testing (POCT) products, low-dose non-injectable interferon therapeutics and synthetic RNA (SRNA)-driven preventive medicine.

Its POCT devices are based on core technologies involving COVID-19 POCT products and other POCT products that detect volatile organic compounds (VOCs) emitted by the human body.

The company was formerly known as Amarillo Bioscience, Inc.

Note: Revenue and net loss figures are for the 12 months ended March 31, 2022.